Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2012, Article ID 972368, 7 pages
http://dx.doi.org/10.1155/2012/972368
Review Article

Sepsis-Induced Adipokine Change with regard to Insulin Resistance

1Department of General, Visceral, and Transplantation Surgery, University Hospital of Ulm, Steinhoevelstraße 9, 89075 Ulm, Germany
2Clinic of Anesthesiology, University Hospital of Ulm, Steinhoevelstraße 9, 89075 Ulm, Germany
3Department of Traumatology, Hand and Reconstructive Surgery, University Hospital of Ulm, Steinhoevelstraße 9, 89075 Ulm, Germany

Received 12 June 2011; Revised 22 September 2011; Accepted 5 October 2011

Academic Editor: Juan Carlos Kaski

Copyright © 2012 Andreas Hillenbrand et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Trayhurn and I. S. Wood, “Adipokines: inflammation and the pleiotropic role of white adipose tissue,” British Journal of Nutrition, vol. 92, no. 3, pp. 347–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. S. E. Wozniak, L. L. Gee, M. S. Wachtel, and E. E. Frezza, “Adipose tissue: the new endocrine organ? a review article,” Digestive Diseases and Sciences, vol. 54, no. 9, pp. 1847–1856, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Hillenbrand, U. Knippschild, M. Weiss et al., “Sepsis induced changes of adipokines and cytokines—septic patients compared to morbidly obese patients,” BMC Surgery, vol. 10, article 26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 85–97, 2011. View at Publisher · View at Google Scholar
  5. M. Owecki, “Fat tissue and adiponectin: new players in critical care?” Critical Care, vol. 13, no. 4, p. 174, 2009. View at Google Scholar · View at Scopus
  6. T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe, “Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1784–1792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Venkatesh, I. Hickman, J. Nisbet, J. Cohen, and J. Prins, “Changes in serum adiponectin concentrations in critical illness: a preliminary investigation,” Critical Care, vol. 13, no. 4, article R105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Yokota, K. Oritani, I. Takahashi et al., “Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages,” Blood, vol. 96, no. 5, pp. 1723–1732, 2000. View at Google Scholar · View at Scopus
  9. M. C. Wulster-Radcliffe, K. M. Ajuwon, J. Wang, J. A. Christian, and M. E. Spurlock, “Adiponectin differentially regulates cytokines in porcine macrophages,” Biochemical and Biophysical Research Communications, vol. 316, no. 3, pp. 924–929, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Yamaguchi, J. G. M. Argueta, Y. Masuhiro et al., “Adiponectin inhibits Toll-like receptor family-induced signaling,” FEBS Letters, vol. 579, no. 30, pp. 6821–6826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Hillenbrand, M. Weiss, U. Knippschild et al., “Association of adiponectin levels and insulin demand in critically ill patients,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 4, pp. 45–51, 2011. View at Publisher · View at Google Scholar
  12. I. Nagaev, M. Bokarewa, A. Tarkowski, and U. Smith, “Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes,” PLoS One, vol. 1, no. 1, article e31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. C. M. Steppan and M. A. Lazar, “Resistin and obesity-associated insulin resistance,” Trends in Endocrinology and Metabolism, vol. 13, no. 1, pp. 18–23, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Patel, A. C. Buckels, I. J. Kinghorn et al., “Resistin is expressed in human macrophages and directly regulated by PPARγ activators,” Biochemical and Biophysical Research Communications, vol. 300, no. 2, pp. 472–476, 2003. View at Publisher · View at Google Scholar
  15. M. H. Fonseca-Alaniz, J. Takada, M. I. Alonso-Vale, and F. B. Lima, “Adipose tissue as an endocrine organ: from theory to practice,” Jornal de Pediatria, vol. 83, no. 5, pp. S192–S203, 2007. View at Google Scholar · View at Scopus
  16. N. Silswal, A. K. Singh, B. Aruna, S. Mukhopadhyay, S. Ghosh, and N. Z. Ehtesham, “Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway,” Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1092–1101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. S. C. Lu, W. Y. Shieh, C. Y. Chen, S. C. Hsu, and H. L. Chen, “Lipopolysaccharide increases resistin gene expression in vivo and in vitro,” FEBS Letters, vol. 530, no. 1-3, pp. 158–162, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Owecki, A. Miczke, E. Nikisch, D. Pupek-Musialik, and J. Sowiski, “Serum resistin concentrations are higher in human obesity but independent from insulin resistance,” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 2, pp. 117–121, 2011. View at Publisher · View at Google Scholar
  19. A. M. van den Hoek, B. Teusink, P. J. Voshol, L. M. Havekes, J. A. Romijn, and H. Pijl, “Leptin deficiency per se dictates body composition and insulin action in ob/ob mice,” Journal of Neuroendocrinology, vol. 20, no. 1, pp. 120–127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. R. Bornstein, J. Licinio, R. Tauchnitz et al., “Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm in cortisol and leptin secretion,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 1, pp. 280–283, 1998. View at Publisher · View at Google Scholar
  21. P. Maruna, R. Gürlich, R. Fraško, and M. Haluzík, “Serum leptin levels in septic men correlate well with C-reactive protein (CRP) and TNF-alpha but not with BMI,” Physiological Research, vol. 50, no. 6, pp. 589–594, 2001. View at Google Scholar
  22. V. Vachharajani, “Influence of obesity on sepsis,” Pathophysiology, vol. 15, no. 2, pp. 123–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Tzanela, S. E. Orfanos, M. Tsirantonaki et al., “Leptin alterations in the course of sepsis in humans,” In Vivo, vol. 20, no. 4, pp. 565–570, 2006. View at Google Scholar · View at Scopus
  24. E. A. Oral, V. Simha, E. Ruiz et al., “Leptin-replacement therapy for lipodystrophy,” The New England Journal of Medicine, vol. 346, no. 8, pp. 570–578, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Bastelica, P. Morange, B. Berthet et al., “Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 1, pp. 173–178, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Bergmann and S. Hammerschmidt, “Fibrinolysis and host response in bacterial infections,” Thrombosis and Haemostasis, vol. 98, no. 3, pp. 512–520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. P. G. Arndt, S. K. Young, and G. S. Worthen, “Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator inhibitor-1 through a JNK-mediated pathway,” Journal of Immunology, vol. 175, no. 6, pp. 4049–4059, 2005. View at Google Scholar · View at Scopus
  28. S. H. Kwak, X. Q. Wang, Q. He et al., “Plasminogen activator inhibitor-I potentiates LPS-induced neutrophil activation through a JNK-mediated pathway,” Thrombosis and Haemostasis, vol. 95, no. 5, pp. 829–835, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. P. W. M. Hermans and J. A. Hazelzet, “Plasminogen activator inhibitor type 1 gene polymorphism and sepsis,” Clinical Infectious Diseases, vol. 41, no. 7, pp. S453–S458, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. L. J. Ma, S. L. Mao, K. L. Taylor et al., “Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1,” Diabetes, vol. 53, no. 2, pp. 336–346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Singer and N. Granger, “Inflammatory responses underlying the microvascular dysfunction associated with obesity and insulin resistance,” Microcirculation, vol. 14, no. 4-5, pp. 375–387, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Franchini, E. Monnais, D. Seboek et al., “Insulin resistance and increased lipolysis in bone marrow derived adipocytes stimulated with agonists of toll-like receptors,” Hormone and Metabolic Research, vol. 42, no. 10, pp. 703–709, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Rotter, I. Nagaev, and U. Smith, “Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects,” Journal of Biological Chemistry, vol. 278, no. 46, pp. 45777–45784, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. J. M. Bruun, S. B. Pedersen, and B. Richelsen, “Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 3, pp. 1267–1273, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Fève and J. P. Bastard, “The role of interleukins in insulin resistance and type 2 diabetes mellitus,” Nature Reviews Endocrinology, vol. 5, no. 6, pp. 305–311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. G. S. Hotamisligil and B. M. Spiegelman, “Tumor necrosis factor α: a key component of the obesity-diabetes link,” Diabetes, vol. 43, no. 11, pp. 1271–1278, 1994. View at Google Scholar · View at Scopus
  37. B. K. Pedersen, M. A. Febbraio, and R. A. Mooney, “Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis,” Journal of Applied Physiology, vol. 102, no. 2, pp. 814–819, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Rabe, M. Lehrke, K. G. Parhofer, and U. C. Broedl, “Adipokines and insulin resistance,” Molecular Medicine, vol. 14, no. 11-12, pp. 741–751, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. Bruun, A. S. Lihn, C. Verdich et al., “Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans,” American Journal of Physiology, vol. 285, no. 3, pp. E527–E533, 2003. View at Google Scholar
  40. K. B. Goralski, T. C. McCarthy, E. A. Hanniman et al., “Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism,” Journal of Biological Chemistry, vol. 282, no. 38, pp. 28175–28188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. L. Cash, R. Hart, A. Russ et al., “Synthetic chemerin-derived peptides suppress inflammation through ChemR23,” Journal of Experimental Medicine, vol. 205, no. 4, pp. 767–775, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. H. John, J. Hierer, O. Haas, and W. G. Forssmann, “Quantification of angiotensin-converting-enzyme-mediated degradation of human chemerin 145-154 in plasma by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry,” Analytical Biochemistry, vol. 362, no. 1, pp. 117–125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Luangsay, V. Wittamer, B. Bondue et al., “Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model,” Journal of Immunology, vol. 183, no. 10, pp. 6489–6499, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Hart and D. R. Greaves, “Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5,” Journal of Immunology, vol. 185, no. 6, pp. 3728–3739, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Sell, J. Laurencikiene, A. Taube et al., “Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells,” Diabetes, vol. 58, no. 12, pp. 2731–2740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. Q. Yang, T. E. Graham, N. Mody et al., “Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes,” Nature, vol. 436, no. 7049, pp. 356–362, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Broch, J. Vendrell, W. Ricart, C. Richart, and J. M. Fernández-Real, “Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects,” Diabetes Care, vol. 30, no. 7, pp. 1802–1806, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Langouche, S. Vander Perre, J. Frystyk, A. Flyvbjerg, T. K. Hansen, and G. van den Berghe, “Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin,” Critical Care, vol. 13, no. 4, article R112, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Koch, R. Weiskirchen, E. Sanson et al., “Circulating retinol-binding-protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation,” Critical Care, vol. 14, p. R179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. Z. B. Deng, A. Poliakov, R. W. Hardy et al., “Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance,” Diabetes, vol. 58, no. 11, pp. 2498–2505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. V. Varma, A. Yao-Borengasser, N. Rasouli et al., “Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 2, pp. 666–672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. T.-Q. Bi and X.-M. Che, “Nampt/PBEF/visfatin and cancer,” Cancer Biology and Therapy, vol. 10, no. 2, pp. 119–125, 2010. View at Publisher · View at Google Scholar
  53. J. K. Sethi, “Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome?” Current Hypertension Reports, vol. 9, no. 1, pp. 33–38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Stofkova, “Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity,” Endocrine Regulations, vol. 44, no. 1, pp. 25–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. S. H. Jia, Y. Li, J. Parodo et al., “Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis,” Journal of Clinical Investigation, vol. 113, no. 9, pp. 1318–1327, 2004. View at Publisher · View at Google Scholar
  56. A. R. Moschen, A. Kaser, B. Enrich et al., “Visfatin, an adipocytokine with proinflammatory and immunomodulating properties,” Journal of Immunology, vol. 178, no. 3, pp. 1748–1758, 2007. View at Google Scholar · View at Scopus
  57. A. R. Moschen, R. R. Gerner, and H. Tilg, “Pre-b cell colony enhancing factor/nampt/visfatin in inflammation and obesityrelated disorders,” Current Pharmaceutical Design, vol. 16, no. 17, pp. 1913–1920, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Kanda, S. Tateya, Y. Tamori et al., “MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity,” Journal of Clinical Investigation, vol. 116, no. 6, pp. 1494–1505, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. F. A. Bozza, J. I. Salluh, A. M. Japiassu et al., “Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis,” Critical Care, vol. 11, article R49, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Brueckmann, A. Marx, H. M. Weiler et al., “Stabilization of monocyte chemoattractant protein-I-mRNA by activated protein C,” Thrombosis and Haemostasis, vol. 89, no. 1, pp. 149–160, 2003. View at Google Scholar · View at Scopus
  61. R. N. Gomes, R. T. Figueiredo, F. A. Bozza et al., “Increased susceptibility to septic and endotoxic shock in monocyte chemoattractant protein 1/CC chemokine ligand 2-deficient mice correlates with reduced interleukin 10 and enhanced macrophage migration inhibitory factor production,” Shock, vol. 26, no. 5, pp. 457–463, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Tateya, Y. Tamori, T. Kawaguchi, H. Kanda, and M. Kasuga, “An increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice,” Endocrinology, vol. 151, no. 3, pp. 971–979, 2010. View at Publisher · View at Google Scholar · View at Scopus